NAMS Menopause Certification (MSCP) Practice 2026/2027 Exam verified with
correct answers and rationales /instant pdf
1. Menopause is clinically defined as:
A. The first irregular menstrual cycle
B. 12 consecutive months of amenorrhea without another identifiable cause
C. 6 months without menstruation in every woman
D. The onset of hot flashes
Correct answer: B. 12 consecutive months of amenorrhea without another identifiable cause
Rationale: Natural menopause is retrospectively diagnosed after 12 consecutive months without
menstruation when another cause is not identified.
2. The menopausal transition is primarily characterized by:
A. Predictable monthly ovulation
B. Changes in menstrual-cycle regularity and ovarian hormone production
C. Permanent elevation of progesterone
D. Complete cessation of ovarian function from the beginning of the transition
Correct answer: B. Changes in menstrual-cycle regularity and ovarian hormone production
Rationale: The menopausal transition involves fluctuating ovarian function, changing hormone
levels, and increasingly irregular menstrual cycles.
3. The most common vasomotor symptom of menopause is:
A. Hot flash
B. Severe hypertension
C. Persistent hypothermia
D. Visual loss
Correct answer: A. Hot flash
Rationale: Vasomotor symptoms, particularly hot flashes and night sweats, are common during
the menopausal transition and postmenopause.
4. A typical hot flash is caused primarily by:
A. A narrowed thermoneutral zone associated with changes in thermoregulatory control
B. Permanent infection
C. Increased bone resorption alone
D. Excessive insulin production
,Correct answer: A. A narrowed thermoneutral zone associated with changes in
thermoregulatory control
Rationale: Menopause-related changes in thermoregulation can make small changes in core
temperature trigger heat-dissipation responses.
5. Which factor may worsen vasomotor symptoms?
A. Certain medications, alcohol, and environmental heat
B. Adequate sleep
C. A cool environment
D. Regular physical activity in all individuals
Correct answer: A. Certain medications, alcohol, and environmental heat
Rationale: Triggers vary, but heat, alcohol, stress, and some medications can worsen hot flashes
in some individuals.
6. Genitourinary syndrome of menopause (GSM) is associated with:
A. Estrogen-related changes affecting vulvar, vaginal, and lower urinary tract tissues
B. Only breast tissue changes
C. Increased vaginal lubrication in all patients
D. A condition that always resolves without treatment
Correct answer: A. Estrogen-related changes affecting vulvar, vaginal, and lower urinary tract
tissues
Rationale: GSM may include vaginal dryness, burning, dyspareunia, urinary urgency, dysuria,
and recurrent urinary tract infections.
7. A patient with GSM reports vaginal dryness and dyspareunia. An appropriate
initial management option may include:
A. Vaginal moisturizers and lubricants
B. Avoiding all sexual activity permanently
C. Systemic antibiotics for every patient
D. Fluid restriction
Correct answer: A. Vaginal moisturizers and lubricants
Rationale: Nonhormonal vaginal moisturizers and lubricants can help relieve dryness and
discomfort. Other therapies may be considered based on symptoms and patient factors.
8. Low-dose vaginal estrogen is primarily used to treat:
,A. Genitourinary symptoms of menopause
B. Acute appendicitis
C. Hyperthyroidism
D. Osteomyelitis
Correct answer: A. Genitourinary symptoms of menopause
Rationale: Local vaginal estrogen can improve symptoms related to estrogen deficiency in
genitourinary tissues.
9. For a patient with an intact uterus using systemic estrogen therapy, a
progestogen is generally added to:
A. Reduce the risk of endometrial hyperplasia and cancer
B. Increase vasomotor symptoms
C. Prevent all breast disease
D. Treat bacterial vaginosis
Correct answer: A. Reduce the risk of endometrial hyperplasia and cancer
Rationale: Unopposed systemic estrogen stimulates the endometrium. Appropriate progestogen
therapy provides endometrial protection.
10. A patient who has had a total hysterectomy generally:
A. May not require a progestogen solely for endometrial protection when using systemic
estrogen
B. Must always take a progestogen with estrogen
C. Cannot use any menopausal hormone therapy
D. Has no need for individualized treatment decisions
Correct answer: A. May not require a progestogen solely for endometrial protection when using
systemic estrogen
Rationale: Without an intact uterus, there is generally no endometrium requiring protection from
estrogen stimulation, although individual clinical circumstances may affect treatment choices.
11. Menopausal hormone therapy is most effective for:
A. Vasomotor symptoms
B. Treating all chronic diseases
C. Preventing every form of cancer
D. Treating bacterial infections
Correct answer: A. Vasomotor symptoms
, Rationale: Systemic hormone therapy is an effective treatment for bothersome vasomotor
symptoms and may provide other benefits depending on the patient.
12. The decision to use menopausal hormone therapy should be based primarily
on:
A. Individualized assessment of benefits, risks, symptoms, age, timing, and medical history
B. A one-size-fits-all treatment plan
C. The patient's age alone
D. A mandatory treatment duration for every patient
Correct answer: A. Individualized assessment of benefits, risks, symptoms, age, timing, and
medical history
Rationale: Menopause care should use shared decision-making and individualized risk-benefit
assessment.
13. A patient with bothersome hot flashes who cannot or does not wish to use
hormone therapy may be offered:
A. Evidence-based nonhormonal therapies
B. No treatment under any circumstances
C. Antibiotics
D. Insulin therapy
Correct answer: A. Evidence-based nonhormonal therapies
Rationale: Several nonhormonal pharmacologic and behavioral approaches may reduce
vasomotor symptoms.
14. Which medication class may be used as a nonhormonal option for vasomotor
symptoms?
A. Selected SSRIs or SNRIs
B. Penicillins
C. Anthelmintics
D. Proton pump inhibitors only
Correct answer: A. Selected SSRIs or SNRIs
Rationale: Certain antidepressants can reduce the frequency or severity of vasomotor symptoms
in appropriate patients.
15. Gabapentin may be useful for some patients with:
correct answers and rationales /instant pdf
1. Menopause is clinically defined as:
A. The first irregular menstrual cycle
B. 12 consecutive months of amenorrhea without another identifiable cause
C. 6 months without menstruation in every woman
D. The onset of hot flashes
Correct answer: B. 12 consecutive months of amenorrhea without another identifiable cause
Rationale: Natural menopause is retrospectively diagnosed after 12 consecutive months without
menstruation when another cause is not identified.
2. The menopausal transition is primarily characterized by:
A. Predictable monthly ovulation
B. Changes in menstrual-cycle regularity and ovarian hormone production
C. Permanent elevation of progesterone
D. Complete cessation of ovarian function from the beginning of the transition
Correct answer: B. Changes in menstrual-cycle regularity and ovarian hormone production
Rationale: The menopausal transition involves fluctuating ovarian function, changing hormone
levels, and increasingly irregular menstrual cycles.
3. The most common vasomotor symptom of menopause is:
A. Hot flash
B. Severe hypertension
C. Persistent hypothermia
D. Visual loss
Correct answer: A. Hot flash
Rationale: Vasomotor symptoms, particularly hot flashes and night sweats, are common during
the menopausal transition and postmenopause.
4. A typical hot flash is caused primarily by:
A. A narrowed thermoneutral zone associated with changes in thermoregulatory control
B. Permanent infection
C. Increased bone resorption alone
D. Excessive insulin production
,Correct answer: A. A narrowed thermoneutral zone associated with changes in
thermoregulatory control
Rationale: Menopause-related changes in thermoregulation can make small changes in core
temperature trigger heat-dissipation responses.
5. Which factor may worsen vasomotor symptoms?
A. Certain medications, alcohol, and environmental heat
B. Adequate sleep
C. A cool environment
D. Regular physical activity in all individuals
Correct answer: A. Certain medications, alcohol, and environmental heat
Rationale: Triggers vary, but heat, alcohol, stress, and some medications can worsen hot flashes
in some individuals.
6. Genitourinary syndrome of menopause (GSM) is associated with:
A. Estrogen-related changes affecting vulvar, vaginal, and lower urinary tract tissues
B. Only breast tissue changes
C. Increased vaginal lubrication in all patients
D. A condition that always resolves without treatment
Correct answer: A. Estrogen-related changes affecting vulvar, vaginal, and lower urinary tract
tissues
Rationale: GSM may include vaginal dryness, burning, dyspareunia, urinary urgency, dysuria,
and recurrent urinary tract infections.
7. A patient with GSM reports vaginal dryness and dyspareunia. An appropriate
initial management option may include:
A. Vaginal moisturizers and lubricants
B. Avoiding all sexual activity permanently
C. Systemic antibiotics for every patient
D. Fluid restriction
Correct answer: A. Vaginal moisturizers and lubricants
Rationale: Nonhormonal vaginal moisturizers and lubricants can help relieve dryness and
discomfort. Other therapies may be considered based on symptoms and patient factors.
8. Low-dose vaginal estrogen is primarily used to treat:
,A. Genitourinary symptoms of menopause
B. Acute appendicitis
C. Hyperthyroidism
D. Osteomyelitis
Correct answer: A. Genitourinary symptoms of menopause
Rationale: Local vaginal estrogen can improve symptoms related to estrogen deficiency in
genitourinary tissues.
9. For a patient with an intact uterus using systemic estrogen therapy, a
progestogen is generally added to:
A. Reduce the risk of endometrial hyperplasia and cancer
B. Increase vasomotor symptoms
C. Prevent all breast disease
D. Treat bacterial vaginosis
Correct answer: A. Reduce the risk of endometrial hyperplasia and cancer
Rationale: Unopposed systemic estrogen stimulates the endometrium. Appropriate progestogen
therapy provides endometrial protection.
10. A patient who has had a total hysterectomy generally:
A. May not require a progestogen solely for endometrial protection when using systemic
estrogen
B. Must always take a progestogen with estrogen
C. Cannot use any menopausal hormone therapy
D. Has no need for individualized treatment decisions
Correct answer: A. May not require a progestogen solely for endometrial protection when using
systemic estrogen
Rationale: Without an intact uterus, there is generally no endometrium requiring protection from
estrogen stimulation, although individual clinical circumstances may affect treatment choices.
11. Menopausal hormone therapy is most effective for:
A. Vasomotor symptoms
B. Treating all chronic diseases
C. Preventing every form of cancer
D. Treating bacterial infections
Correct answer: A. Vasomotor symptoms
, Rationale: Systemic hormone therapy is an effective treatment for bothersome vasomotor
symptoms and may provide other benefits depending on the patient.
12. The decision to use menopausal hormone therapy should be based primarily
on:
A. Individualized assessment of benefits, risks, symptoms, age, timing, and medical history
B. A one-size-fits-all treatment plan
C. The patient's age alone
D. A mandatory treatment duration for every patient
Correct answer: A. Individualized assessment of benefits, risks, symptoms, age, timing, and
medical history
Rationale: Menopause care should use shared decision-making and individualized risk-benefit
assessment.
13. A patient with bothersome hot flashes who cannot or does not wish to use
hormone therapy may be offered:
A. Evidence-based nonhormonal therapies
B. No treatment under any circumstances
C. Antibiotics
D. Insulin therapy
Correct answer: A. Evidence-based nonhormonal therapies
Rationale: Several nonhormonal pharmacologic and behavioral approaches may reduce
vasomotor symptoms.
14. Which medication class may be used as a nonhormonal option for vasomotor
symptoms?
A. Selected SSRIs or SNRIs
B. Penicillins
C. Anthelmintics
D. Proton pump inhibitors only
Correct answer: A. Selected SSRIs or SNRIs
Rationale: Certain antidepressants can reduce the frequency or severity of vasomotor symptoms
in appropriate patients.
15. Gabapentin may be useful for some patients with:
